Advertisement


Andrew Seidman, MD, and Eric Winer, MD, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

2015 San Antonio Breast Cancer Symposium

Advertisement

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).



Related Videos

Breast Cancer

Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).

Breast Cancer

Lisa Carey, MD, and Sibylle Loibl, MD, PhD: Update on Metastatic Disease

Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).

Breast Cancer

William M. Sikov, MD, FACP, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).

Breast Cancer

Clifford Hudis, MD, and Carlos Arteaga, MD, on Metabolic Syndrome and Obesity in Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.

Breast Cancer

Lisa Carey, MD, and Jay Harris, MD, on Critical Decision Making in Radiation Therapy for Breast Cancer

Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.

Advertisement

Advertisement




Advertisement